Pharmacological hypogonadism impairs molecular transducers of exercise-induced muscle growth in humans

Nima Gharahdaghi1, Supreeth Rudrappa1, Matthew S. Brook1, Wesam Farrash1,2, Iskandar Idris1, Muhammad Hariz Abdul Aziz1, Fawzi Kadi3, Konstantinos Papaioannou3, Bethan E. Phillips1, Tanvir Sian1, Philip J. Herrod1, Daniel J. Wilkinson1, Nathaniel J. Szewczyk1, Kenneth Smith1 & Philip J. Atherton1*

1MRC-Verus Arthritis Centre for Musculoskeletal Ageing Research and Nottingham NIHR BRC, School of Medicine, University of Nottingham, Derby, UK; 2Laboratory Medicine Department, College of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia; 3Division of Sports Sciences, School of Health and Medical Sciences, Örebro University, Örebro, Sweden

Abstract

Background The relative role of skeletal muscle mechano-transduction in comparison with systemic hormones, such as testosterone (T), in regulating hypertrophic responses to exercise is contentious. We investigated the mechanistic effects of chemical endogenous T depletion adjuvant to 6 weeks of resistance exercise training (RET) on muscle mass, function, myogenic regulatory factors, and muscle anabolic signalling in younger men.

Methods Non-hypogonadal men (n = 16; 18–30 years) were randomized in a double-blinded fashion to receive placebo (P, saline n = 8) or the GnRH analogue, Goserelin [Zoladex (Z), 3.6 mg, n = 8], injections, before 6 weeks of supervised whole-body RET. Participants underwent dual-energy X-ray absorptiometry (DXA), ultrasound of m. vastus lateralis (VL), and VL biopsies for assessment of cumulative muscle protein synthesis (MPS), myogenic gene expression, and anabolic signalling pathway responses.

Results Zoladex suppressed endogenous T to within the hypogonadal range and was well tolerated; suppression was associated with blunted fat free mass [Z: 55.4 ± 2.8 to 55.8 ± 3.1 kg, P = 0.61 vs. P: 55.9 ± 1.7 to 57.4 ± 1.7 kg, P = 0.006, effect size (ES) = 0.31], composite strength [Z: 40 ± 2.3% vs. P: 49.8 ± 3.3%, P = 0.03, ES = 1.4], and muscle thickness (Z: 2.7 ± 0.4 to 2.69 ± 0.36 cm, P > 0.99 vs. P: 2.74 ± 0.32 to 2.91 ± 0.32 cm, P < 0.0001, ES = 0.48) gains. Hypogonadism attenuated molecular transducers of muscle growth related to T metabolism (e.g. androgen receptor: Z: 1.2 fold, P > 0.99 vs. P: 1.9 fold, P < 0.0001, ES = 0.85), anabolism/myogenesis (e.g. IGF-1Ea: Z: 1.9 fold, P = 0.5 vs. P: 3.3 fold, P = 0.0005, ES = 0.72; IGF-1Ec: Z: 2 fold, P > 0.99 vs. P: 4.7 fold, P = 0.0005, ES = 0.68; myogenin: Z: 1.3 fold, P > 0.99 vs. P: 2.7 fold, P = 0.002, ES = 0.72), RNA/DNA (Z: 0.47 ± 0.03 to 0.53 ± 0.03, P = 0.31 vs. P: 0.5 ± 0.01 to 0.64 ± 0.04, P = 0.003, ES = 0.72), and RNA/ASP (Z: 5.8 ± 0.4 to 6.8 ± 0.5, P > 0.99 vs. P: 6.5 ± 0.2 to 8.9 ± 1.1, P = 0.008, ES = 0.63) ratios, as well as acute RET-induced phosphorylation of growth signalling proteins (e.g. AKTser473: Z: 2.74 ± 0.6, P = 0.2 vs. P: 5.5 ± 1 fold change, P < 0.001, ES = 0.54 and mTORC1ser2448: Z: 1.9 ± 0.8, P > 0.99 vs. P: 3.6 ± 1 fold change, P = 0.002, ES = 0.53). Both MPS (Z: 1.45 ± 0.11 to 1.50 ± 0.06%·day−1, P = 0.99 vs. P: 1.5 ± 0.12 to 2.0 ± 0.15%·day−1, P = 0.01, ES = 0.97) and (extrapolated) muscle protein breakdown (Z: 93.16 ± 7.8 vs. P: 129.1 ± 13.8 g·day−1, P = 0.04, ES = 0.92) were reduced with hypogonadism result in lower net protein turnover (3.9 ± 1 vs. 1.2 ± 1 g·day−1, P = 0.04, ES = 0.95).

Conclusions We conclude that endogenous T sufficiency has a central role in the up-regulation of molecular transducers of RET-induced muscle hypertrophy in humans that cannot be overcome by muscle mechano-transduction alone.

© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Introduction

Skeletal muscle functions as a motor for locomotion and regulator of whole-body metabolism. Catabolic conditions in skeletal muscle, for example, ageing, disease, cachexia, and denervation, lead to muscle atrophy accompanied by disability, loss of independence, morbidity, and mortality. The regulatory factors that maintain muscle mass, both structurally and metabolically, dictate the balance between muscle protein synthesis (MPS) and breakdown (MPB). In turn, muscle proteostasis is under the influence of a myriad of factors such as nutrition, hormonal milieu, injury, disease, and exercise. In terms of the latter, a major focus has—and remains—the control of muscle mass and the use of resistance exercise training (RET) as a countermeasure for muscle atrophy. Nonetheless, the central mechanisms of successful muscle maintenance and growth remain contentious.

The two major routes to muscle growth are (i) hormonal/humoral and (ii) mechano-pathways. Mechano-transduction describes the conversion of physically induced factors (e.g. stretch/active-contraction) into chemical messengers to aid the cell to mount an appropriate response via modulation of target transcription and mRNA translation. One of the most widely recognized players in controlling MPS (and by extension, mass) is the mechanistic target of rapamycin (mTOR) pathway, indicating the essentiality of post-translational signalling pathways in relation to MPS. Reflecting this, mTOR complex 1 (mTORC1) co-ordinates cellular remodelling processes of growth, differentiation, autophagy, and survival via its substrates [e.g. ribosomal S6 kinase 1 (S6K1) and 4E-binding protein 1 (4EBP1)]. mTORC1 activation is triggered by the IGF-1–PI3K–Akt signalling pathway where insulin-like growth factor 1 (IGF-1) binds to its receptor and phosphorylates phosphatidylinositol 3-kinase (PI3K), which in turn activates protein kinase B (Akt). mTORC1 may also be activated following mechanical overload but independently of the IGF-1–PI3K–Akt pathway, without Akt phosphorylation or with reduced activation after RE in the fasted state, despite downstream activation of mTORC1. mTORC1 activation at the early phase of mechanical overload via mitogen activated kinase/extracellular signal-regulated kinase (MEK/ERK)/tuberous sclerosis protein 2 (TSC2) signalling is also associated with delayed increases in total RNA content (~5 days) and muscle hypertrophy in rats. Muscle growth is also regulated by temporal transcriptional remodelling during RET. However, the upstream drivers, that is, the stimulatory molecular transducers of muscle growth, are a myriad, and the integrated effects of hormones (e.g. androgens) and mechano-transduction processes remain to be fully elucidated.

Hormones, androgens specifically, are established regulators of protein turnover, through genomic (transcriptional capacity) and non-genomic (translational efficiency) pathways. Exemplifying this, androgen deprivation therapy was associated with a decrease in fat free mass (FFM) and increase in fat mass. We also showed that older men with lower baseline levels of endogenous testosterone (T) exhibited blunted adaptation to RET, which could be overcome with exogenous T administration, thus suggesting a major role for T in the regulation of molecular transducers of human muscle growth. Similarly, irrespective of age, reducing endogenous T levels to a castration range for 12 weeks blunted FFM and strength gains in young men. However, other work points to a limited role of T in mRNA translation and muscle growth, and in relation to RE. For instance, post-RE elevations in T were not associated with increases in FFM, fibre cross-sectional area (CSA), or strength after 12 weeks of RET, while a ‘high’ versus ‘low’ hormone environment (induced by working distinct muscle bulk) did not enhance hypertrophy or strength in young men. Finally, RE-induced increases in endogenous T did not enhance anabolic signalling or acute MPS responses. It is extraordinary that a major area of contention remains the role of endogenous T in exercise-induced muscle growth, for example, in comparison with non-centrally mediated effectors (mechano-transduction). To resolve this, we studied the impacts of RET under pharmaceutical hypogonadism (NB. not, depletion) in younger men, while determining endpoints relating to muscle mass, function, myogenic regulation, anabolic signalling, and protein turnover. Our study design permitted determination of the impact of hypogonadism, with a translational relevance.

Materials and methods

Study overview and participants details

This study was approved by The University of Nottingham Faculty of Medicine and Health Sciences Research Ethics Committee (G11082015 SoMS MSGEM), was conducted according to the Declaration of Helsinki, and was pre-registered at clinicaltrials.gov (NCT02152839). Before entry into the study,
participants provided written informed consent to participate after all procedures and risks were explained to them. All participants were screened by medical questionnaire, physical examination, routine blood chemistry, and a resting electrocardiogram, and those who presented with metabolic, respiratory, or cardiovascular disorders or who were prescribed chronic medication (e.g. beta-adrenergic blocking agents, statins, and anti-inflammatory drugs) or any other medication that could influence T metabolism were excluded.

Following baseline measurements of maximal voluntary contraction (MVC) and 1-repetition maximum (1-RM; on separate days), regardless of group assignment, all participants were further characterized at baseline. This involved collection of a fasting blood sample, muscle ultrasound (Mylab 70; Esaote Biomedica, Italy) of the m. vastus lateralis muscle (VL), and a dual-energy X-ray absorptiometry (DXA; Lunar Prodigy II, GE Medical Systems, Little Chalfont, UK) scan. Finally, a unilateral muscle biopsy was taken under rested conditions from the VL. In order to assess rates of MPS, a basal saliva sample was collected before the muscle biopsy, and the first dose of D$_2$O as a bolus of 3 mL·kg$^{-1}$ body weight was consumed by participants after the biopsy. The initial priming dose of D$_2$O was followed by daily small-volume ‘top-ups’ of ~20 mL (calculated from measures of each individual’s body water pool turnover). Finally, a subcutaneous injection of Zoladex or saline placebo (P) was administered by an unblinded clinical research fellow; in order to identify any potential side effects of the Zoladex administration, they were not involved in any other aspect of the study. The fully supervised RET protocol then commenced and continued for the next 6 weeks. Additional VL biopsies (60 min after bouts of RE to obtain temporal acute effects of RE across RET) and other tests/samples took place intermittently during these 6 weeks. A detailed schematic of the study protocol is depicted in Figure 1. All muscle samples were collected under sterile conditions, using the conchotome biopsy technique with 1% w·v$^{-1}$ lidocaine as local anaesthetic. Any fat tissue and connective tissue were rapidly dissected out, and muscle was washed in ice-cold phosphate-buffered saline (PBS) and frozen in liquid nitrogen or liquid-nitrogen cooled isopentane, before storage at –80°C. All participants involved in the study were monitored throughout the study, by the CRF, for any negative side effects of Z. No adverse events were reported during or after completion of the study. Physiological characteristics of participants are shown in Table 1.

---

**Table 1** Participants’ physiological characteristics before and after resistance exercise training

<table>
<thead>
<tr>
<th></th>
<th>Z (n = 8)</th>
<th>P (n = 8)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline</strong></td>
<td><strong>Week 6</strong></td>
<td><strong>Baseline</strong></td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>22.2 (0.8)</td>
<td>21.1 (1.2)</td>
</tr>
<tr>
<td><strong>Height (m)</strong></td>
<td>1.7 (0.1)</td>
<td>1.8 (0.1)</td>
</tr>
<tr>
<td><strong>Weight (kg)</strong></td>
<td>72.9 (4.1)</td>
<td>74.1 (4.3)</td>
</tr>
<tr>
<td><strong>BMI (kg·m$^{-2}$)</strong></td>
<td>23.1 (1.1)</td>
<td>23.4 (1.1)</td>
</tr>
</tbody>
</table>

Values are means (SEM). BMI, body mass index.

---

![Figure 1](#) Detailed schematic of the study protocol.
Physiological and functional measurements

Resistance training procedures and strength measurement
Participants in both groups performed the same whole-body RET including leg extension, leg press, lat pull-down, shoulder press, and bench press (all 3 sets of 8–10 reps at 80% 1-RM) three times per week on non-consecutive days for 6 weeks as a well-established model of hypertrophy. Individuals’ 1-RM was re-assessed every 2 weeks before a training session to maintain intensity with progression. An isokinetic dynamometer (Isocom; Isokinetic Technologies, Eurokinetics, UK) was used to assess isometric knee extensor torque during MVC using three knee joint angles (60°, 70°, and 80°), with full extension corresponding to 0°. Each individual muscle contraction lasted 4 s, with 30 s of rest between contractions, and 90 s between different knee joint angle assessments. In addition, specific strength (total strength–FFM \(^{-1}\)) was calculated as total strength divided by total FFM.

Muscle architecture by ultrasound and dual-energy X-ray absorptiometry-derived fat free mass
Every 10 days and immediately before a training session (e.g. ~72 h after last training session), B-mode ultrasonography (Mylab 70, Esaote Biomedica) with a 100 mm, 10–15 MHz, linear array probe was used for quantification of myo-architecture. Images were obtained at 50% of the VL length and the mid-sagittal line while the participant was lying supine on a couch. To assess fascicle length (Lf), the transducer was aligned with the fascicles to facilitate optimal image capture of the fascicle. The intersection between fascicles and the deep tendon aponeurosis and the perpendicular distance between the superficial and the deep tendon aponeurosis were used to assess pennation angle (PA) and muscle thickness (MT), respectively. Finally, extended-field-of-view ultrasoundography (EFOV) was used to quantify the CSA of the quadriceps. ImageJ software (ImageJ 1.51h) was used to analyse the ultrasound images.

Before and after the study (i.e. ~72 h after last training session), DXA (64752, GE Medical Systems-Lunar Prodigy, US) was used to determine total FFM, leg FFM, total fat percentage (TFP), total fat mass (TFM), FFM index [FFM divided by height squared (FFM·height\(^{-2}\))], and appendicular FFM (FFM of arms and legs in kilograms divided by square of height in metres). Participants were asked to attend having fasted overnight and not performed any heavy physical activity 24 h prior to scanning. For the DXA scan, participants wore loose comfortable clothing with no metal or plastic zippers, buttons, or snaps. Prior to use on participants, a QA block phantom was used to calibrate the system, to ensure optimal measurement. In addition, spine phantoms were run monthly to ensure the reproducibility and accuracy of the system over time.

Metabolic and biochemical measurements

Testosterone enzyme-linked immunosorbent assay
Venous blood samples were collected into EDTA-coated tubes intermittently during the study, that is, before injections and prior to individual RE sessions in the morning to measure fluctuations in total T concentrations. Blood samples were immediately cold centrifuged at 1750 g, with resulting plasma fractions aliquoted and frozen at −80°C until further analysis. An enzyme-linked immunosorbent assay (ELISA; RES2151, IBL, Germany) competitive technique was used to assess the abundance of total T in the plasma of all participants. The intra-assay coefficient of variation was <5%, the assay sensitivity was 70 ng·dL\(^{-1}\), and the detection range was 20–1154 ng·dL\(^{-1}\).

Muscle immunohistochemistry
Serial 5-μm-thick VL muscle cross-sections were cut at ~20°C using a cryostat (Leica, CM 1850, Germany), mounted on glass slides, and air-dried at room temperature. Determination of fibre type-specific CSA, myonuclear, and satellite cell number was performed using monoclonal antibodies against slow (BA-F8) and fast myosin (SC-71), laminin (D18), and Pax-7 (Developmental Studies Hybridoma Bank). Visualization of the primary antibodies was achieved by incubation with Alexa Fluor 488 for BA-F8 and D18 and with Alexa Fluor 568 for SC-71 goat-anti-mouse secondary antibodies (Invitrogen A/S) in situ. Visualization of Pax-7 was performed after incubation with DAB. Myonuclei were stained with DAPI. Muscle sections were then mounted with Molecular Probes Prolong Gold antifade reagent (Invitrogen A/S). Three major fibre types (I, IIA, and IIX) were determined as previously described. Fibre area was measured using Sigma Scan Pro 5 software.

Body water and myofibrillar protein-bound alanine enrichment to determine muscle protein synthesis
To determine the exact volume of D\(_2\)O to be consumed for daily ‘top-ups’, each participant provided saliva for the first 3 days after initial D\(_2\)O consumption. These were processed to determine each participant’s body water decay rate, and from this, the amount of D\(_2\)O needed to maintain a steady state over the study period could be calculated. Individuals were then provided with stocks of daily D\(_2\)O ‘top-ups’ (~10% initial bolus dose) with thrice weekly saliva collection for rest of the study period. Wilkinson et al. previously described how body water and muscle protein enrichment were analysed. Briefly, 80–90 μL of saliva was heated in inverted 2 mL of autosampler vials for 4 h at 90–100°C to evaporate the body water. The vials were then cooled on ice, and the condensate, that is, body water, was transferred to a clean autosampler vial for injection. A high-temperature conversion elemental analyser (Thermo Finnigan, Thermo Scientific, Hemel Hempstead, UK) connected to an isotope ratio mass
Hypogonadism impairs exercise-induced muscle growth

To assess protein bound alanine muscle fraction enrichment, ~40 mg of muscle was homogenized in ice-cold homogenization buffer (Supporting Information, Table S2) to isolate myofibrillar proteins. Briefly, 10 min of rotary mixing was followed by centrifugation at 11 000 g for 15 min at 4°C, the supernatant (sarcoplasmic fraction) was then collected for immunoblotting, and the pellet was re-suspended in 500 µL of mitochondrial extraction buffer (MEB) (Table S2), then homogenized by Dounce, and centrifuged at 1000 g for 5 min at 4°C. Insoluble collagen was separated following centrifugation from myofibrillar proteins that were solubilized in 750 µL of 0.3 N NaOH and subsequently precipitated using 1 M perchloric acid (PCA) then pelleted by centrifugation. Following overnight hydrolysis at 110°C in a 0.1 M HCl and Dowex H+ resin slurry, the amino acids were eluted diluted from the total number of hydrogens in the derivative, excess (APE) of alanine in myo
calcium was calculated from the deuterium enrichment [i.e. atom per cent excess (APE)] of alanine in myofibrillar proteins (APE, corrected for the mean number of deuterium moieties incorporated per alanine; 3.7, and the dilution from the total number of hydrogens in the derivative, i.e. 11) as the precursor labelling between subsequent biopsies. The fractional synthetic rate (FSR) was calculated as follows:

\[
\text{FSR}(\% \cdot \text{day}^{-1}) = -\ln \left( \frac{1 - \left( \frac{\text{APE}_{\text{Ab}}}{\text{APE}_{\text{P}}} \right)}{t} \right),
\]

where \( \text{APE}_{\text{Ab}} \) is deuterium enrichment of protein-bound alanine, \( \text{APE}_{\text{P}} \) is mean precursor enrichment of the body water over the period, and \( t \) is the time between biopsies.

Absolute synthetic rate (ASR) was estimated as

\[
\text{ASR}(g \cdot \text{day}^{-1}) = \frac{\text{FSR}}{100} \times \text{Total.FFM} \times \frac{12.4}{100},
\]

where alkali soluble protein of 12.4% total FFM was assumed.12,13 Absolute protein breakdown rate (ABR) was estimated as:

\[
\text{ABR}(g \cdot \text{day}^{-1}) = \frac{\text{FBR}}{100} \times \text{Total.FFM} \times \frac{12.4}{100},
\]

where fractional breakdown rate (FBR) is calculated as FSR – FGR, with the fractional growth rate (FGR) assumed to be % FFM gain per day over 7 weeks derived by DXA. In addition, the net protein turnover was calculated as ASR – ABR.

**Muscle RNA, DNA, and protein content**

Approximately 15 mg of dry weight muscle was used to determine alkaline soluble protein (ASP), RNA, and DNA content. Initially, 0.2 M PCA was used to homogenize tissue, followed by centrifugation at 11 680 g. Pellets were re-solubilized in 0.3 M NaOH and protein content quantified by spectrophotometry (NanoDrop Lite, Thermo Scientific). Thereafter, the resulting supernatant was used for RNA quantification at 260 nm by spectrophotometry; the pellet was then heated at 70°C for 1 h in 2 M PCA to extract the DNA and centrifuged, and DNA was quantified at 268 nm by spectrophotometry.12,13

**Immunoblotting for anabolic/catabolic signalling**

Spectrophotometry was used to determine protein concentrations of sarcoplasmic fractions, and samples were diluted with 3× Laemmli loading buffer (Table S2) to 1 mg·mL−1, followed by heating at 50°C for 5 min for measuring oxidative phosphorylation (OxPhos) and 95°C for 5 min in order to measure other anabolic and catabolic targets. Precisely 10 µg of samples were loaded onto Criterion XT Bis–Tris–12% SDS-PAGE gels (Bio-Rad) for electrophoresis at 185 V for 45 min. After electrophoresis, as previously described,21 samples were transferred onto polyvinylidene difluoride (PVDF) membranes for 45 min at 100 V. Subsequently, 2.5% low-fat milk that was diluted in Tris-buffered saline Tween-20 (TBST) was used to soak and block PVDF membranes for 1 h at ambient room temperature and then incubated in the following primary antibodies (Table S2) overnight at 4°C (1:2000 dilution in 2.5% BSA in TBS-T): rabbit, androgen receptor (AR) (#3202), phospho-protein kinase B (Akt)Ser473 (#9271), phospho-mechanistic target of rapamycin (mTOR)Ser2448 (#2971), phospho-p70 S6 Kinase (p70S6K)Thr389 (#9234), phospho-4E-BP1 Thr37/46 (#2855), phospho-AMP-activated protein kinase (AMPKae)Thr172 (#2531), phospho-AMP-activated protein kinase (AMPKae)Thr172 (#2531), phospho-AMP-activated protein kinase (AMPKae)Thr172 (#2531), phospho-regulatory associated protein of mTOR (Raptor)Ser792 (#2083), phospho-tuberin/TSC2Thr1462 (#3617), phospho-forkhead box O3 (FoxO3a)Ser253 (#13129) (all from Cell Signaling Technology, Leiden, The Netherlands), and OXPhos rodent antibody Cocktail (ab110413, Abcam, Cambridge, MA). After overnight incubation, membranes were washed for 3 × 5 min in TBS-T and soaked in horseradish peroxidase (HRP)-conjugated secondary antibody [New England Biolabs; 1:2000 in 2.5% bovine serum albumin (BSA) in TBS-T] for 1 h, before 3 × 5 min washes in TBS-T. In order to quantify band intensity (Chemidoc MP, Bio-Rad,
Gene expression analysis of myogenic, insulin-like growth factor 1 related, and testosterone processing

Approximately 10 mg of muscle was homogenized, with one stainless steel bead (Tissue Lyser II, Qiagen, UK), for 2 min at frequency of 30 s⁻¹ in 500 μL of TRIzol (Life Technologies/Thermo Fisher Scientific) to isolate total RNA according to the manufacturer’s instructions. A high-capacity cDNA reverse transcription kit (Life Technologies) was used to reverse-transcribe 500 ng of total RNA for quantitative reverse transcription PCR. Precisely 1 μL of 1:10 diluted cDNA was added in each well of 384-optical well plates (Life Technologies). Exon-exon boundary-specific primers were mixed with SYBR Select Master Mix (LifeTechnologies) and RNase-free water, and 6 μL of the mixed solution, as well as 1 μL of each cDNA were added to each well, with samples run in triplicate. The ViiATM 7 Real-Time PCR System (Life Technologies) was used according to the following thermal cycling conditions: 2 min at 50°C; 2 min at 95°C; 40 cycles of 15 s at 95°C; and 60 s at 60°C. The ΔΔCt method was used to quantify target mRNA expression with Peptidylprolyl-isomerase-A levels measured to correct for variations in RNA input/cDNA synthesis. Primer sequences for each of the probed genes are listed in Table S1.

Statistical analyses

Data are expressed as mean ± SEM, while normality of distribution was examined using the Kolmogorov–Smirnov test. In addition, two-way analysis of variance (ANOVA) and repeated measure ANOVA (time) with one between-subject factor (group) were used to compare the changes during the RET programme both within and between the two (P vs. Z) groups. In addition, independent t-tests were used for comparing fold change between the two groups. Cohen’s effect sizes (ESs) were also calculated for significant data. ESs of 0 to <0.20 were considered ‘trivial’, 0.20 to <0.50 were considered ‘small’, 0.50 to <0.80 were ‘medium’, and ≥0.80 were ‘large’. Where significant differences were found using repeated measure ANOVA, a t-test with Bonferroni correction for multiple comparisons was applied. Correlation was assessed using the Pearson’s product moment correlation coefficient, and intraclass correlation coefficient (ICC) was used to test reliability of DXA and ultrasound-related outputs. The significance level was defined as P ≤ 0.05, and all of the statistical analyses were performed using GraphPad Prism 7.01 (La Jolla, CA).

Results

Baseline characteristics of participants and chemically induced hypogonadism

All participants performed activities of daily living and were recreationally active, but had not participated in RET during the previous 12 months. Of those screened and deemed eligible for participation, 16 non-hypogonadal (morning serum T concentrations of >230 ng·dL⁻¹) healthy young men (age: 21.6 ± 0.7 years, weight: 74.3 ± 2.9 kg, height: 1.8 ± 0.1 m; Table 1) were assigned in a random double-blinded fashion to receive either a one-off: placebo (P, n = 8) or GnRH analogue: Goserelin, so called Zoladex (Z) (3.6 mg, n = 8) injection before 6 weeks of whole-body RET. Goserelin prevents the reappearance of luteinizing hormone releasing hormone (LHRH) receptors and, thus, inhibits the secretion of LH from the pituitary gland and consequently testicular production of T. While most previous human studies suppressed total T levels to within a castration range, T concentrations in our Z group were intended to be lower than in the P group at all time-points during RET (P < 0.05), while also achieving physiological hypogonadism in order to maintain the translational relevance of the study (i.e. rather than eradicating circulatory T; e.g. Z group: 377 ± 31 ng·dL⁻¹ at baseline, 287 ± 61 ng·dL⁻¹ at Week 1, and 45 ± 4 ng·dL⁻¹ at Week 4 and returning to 229 ± 48 ng·dL⁻¹ at the end of RET and finally to the baseline levels after finishing the study) (Figure 2I).

Induced hypogonadism attenuates muscle growth and functional adaptations to resistance exercise training

The DXA (ICC = 0.97) results showed total FFM gains were attenuated significantly following 6 weeks of RET in Z (55.9 ± 1.7 to 57.4 ± 1.7 kg, P = 0.61) compared with P (55.9 ± 1.7 to 57.4 ± 1.7 kg, P = 0.006, ES = 0.31, treatment-by-time interaction: P = 0.04, Figure 2II.A) with a high correlation between FFM gain and average T concentration over the 6 weeks of RET (Figure 2II.D). There was a trend for leg FFM to increase with P only (P: 18.7 ± 0.7 to 19.4 ± 0.7 kg, P = 0.09 vs. Z: 18.9 ± 1.1 to 19 ± 1.2 kg, P > 0.99, Figure 2II.B). Both FFM index (P: 17 ± 0.4 to 17.4 ± 0.5 kg·m⁻², P = 0.007, ES = 0.28 vs. Z:17.5 ± 0.5 to 17.6 ± 0.6 kg·m⁻², P = 0.7, Figure S1) and TFP (P: 23.2 ± 2 to 22.1 ± 2%, P = 0.04, ES = 0.37 vs. Z: 23 ± 2 to 23.6 ± 2%, P = 0.2, treatment-by-time interaction: P = 0.04, Figure 2II.C) adaptation during RET was blunted with chemically induced hypogonadism.

Hypogonadism blunted local muscle remodelling measures (ICC = 0.95) compared with P [muscle thickness (MT), Z:
Hypogonadism impairs exercise-induced muscle growth

I. Total T levels

II. Body Composition

IV. Muscle Fiber Type

II. Muscle Architecture

V. Muscle Strength

A

B

C

D

Placebo

Zoladex

Journal of Cachexia, Sarcopenia and Muscle 2021
DOI: 10.1002/jcsm.12843
2.7 ± 0.4 to 2.69 ± 0.36 cm, P < 0.99 vs. P: 2.74 ± 0.32 to 2.91 ± 0.32 cm, P < 0.0001, ES = 0.48, with a significant difference between two groups (P < 0.0001) and treatment-by-time interaction effect (P < 0.0001); fascicle length (Lf), Z: 7.39 ± 1.1 to 7.42 ± 1.1 cm, P > 0.99 vs. P: 7.91 ± 0.87 to 8.44 ± 0.82 cm, P < 0.0001, ES = 0.34, with a significant difference between two groups (P = 0.003) and treatment-by-time interaction effect (P = 0.003); pennation angle (PA), Z: 24.4 ± 4.1 to 25.2 ± 4.1°, P = 0.32 vs. P: 22.8 ± 1.8 to 24.3 ± 2.27°, P = 0.001, ES = 0.36 and CSA, Z: 80.5 ± 15.4 to 78.8 ± 16.4 cm², P > 0.99 vs. P: 79.1 ± 11.8 to 83.8 ± 9.1 cm², P = 0.005, ES = 0.45, with a significant difference between two groups (P = 0.0007) and treatment-by-time interaction effect (P = 0.007), Figure 2IV.A–D).

The percentage of fibre type IIX did not change by RET with hypogonadism but decreased in P [Z: 15.1 ± 1.5 to 12.1 ± 2.1%, P = 0.15 vs. P: 19.4 ± 3.5 to 15.1 ± 2.5%, P = 0.03, ES = 0.48, with a treatment-by-time interaction effect (P = 0.0006)] without changes in type I and IIA in either group (Figure 2IV.A–D). Type IIA fibre CSA did not change significantly in any group with RET; but hypogonadism bluntly increased in type I fibre CSA (Z: 5276 ± 492 to 5575 ± 965 μm², P = 0.47 vs. P: 4953 ± 285 to 5705 ± 275 μm², P = 0.01, ES = 0.48, Figure 2IV.E,F) with a lack of correlation between quadriiceps CSA and type I and IIA CSA with hypogonadism compared with P (Figure 2IV.H, I). Finally, there were no significant differences in relative satellite cell number (fibre type I: P > 0.99 and fibre type II: P > 0.99, Figure 2IV.F) and myonuclei number (fibre type I: P = 0.67 and fibre type II: P > 0.99, Figure 2IV.F) between the groups.

Dynamic strength (total 1-RM across six exercises) was attenuated with hypogonadism compared with P (Z: 40 ± 2.3% vs. P: 49.8 ± 3.3%, P = 0.03, ES = 1.4, Figure 2V.A) with a lack of correlation between T levels and strength with hypogonadism (Figure 2V.D). There were no significant differences in static strength between the groups (MVC at 70°, P = 0.22, Figure 2V.B), with a similar increase in specified strength (strength per unit area) across the groups (Figure 2V.C).

**Hypogonadism attenuates muscle protein turnover increases to resistance exercise training**

There was a blunted augmentation in cumulative myofibrillar MPS with hypogonadism compared with P over 6 weeks of RET (Z: 1.45 ± 0.11 to 1.5 ± 0.066-day⁻¹, P = 0.99 vs. P: 1.5 ± 0.12 to 2 ± 0.15%-day⁻¹, P = 0.01, ES = 0.97, treatment-by-time interaction: P = 0.06, Figure 3A), in line with findings of blunted FGR in Z compared with P (Z: 0.01 ± 0.01%-day⁻¹ vs. P: 0.05 ± 0.01%-day⁻¹, P = 0.04, ES = 0.43, Figure 3B). Furthermore, ASR was not changed a result of RET in Z (Z: 99.9 ± 9.5 to 94.3 ± 7.8 g·day⁻¹, P > 0.99), but was in P (P: 104.6 ± 10.1 to 133.1 ± 13.9 g·day⁻¹, P = 0.03, ES = 0.32, Figure 3C), with a significant difference between two groups (P = 0.03) and treatment-by-time interaction effect (P = 0.03). In addition, estimated ABR was lower in Z than P during RET (Z: 93.16 ± 7.8 vs. 129.1 ± 13.8 g·day⁻¹, P = 0.04, ES = 0.92, Figure 3D). Finally, net protein turnover with hypogonadism was lower than the P group (3.9 ± 1.1 vs. 1.2 ± 1.1 g·day⁻¹, P = 0.04, ES = 0.95, Figure 3E).

**Hypogonadism impairs the mechanically induced increases in total RNA**

There were no changes in ASP or DNA concentrations per dry weight muscle (μg·mg⁻¹) in Z or P with RET; nonetheless, total RNA content (Z: P = 0.38 vs. P: P < 0.0001, ES = 0.75) and RNA:DNA ratio (Z: P = 0.31 vs. P: P = 0.003, ES = 0.72) increased only in the P group, with significant differences between two groups (P < 0.05) and treatment-by-time interaction effect (P = 0.01). Similarly, RNA:ASP ratio increased in P (P = 0.008, ES = 0.63) but not with hypogonadism (P > 0.99) over the RET. Finally, the ratio of ASP:DNA, a measure of cell size, did not change in either group (Table 2). These results indicate that the increase in translational capacity may be blunted during hypogonadism.

**Hypogonadism impairs the mechanically induced augmentation in signalling proteins**

A measure of AR displayed a decrease at 6 weeks in Z, with no significant changes in P group (Z: 0.8 ± 0.01, P = 0.01, ES = 0.79 vs. P: 1.01 ± 0.07 fold change, P > 0.99, Figure 4A). Compared with P, there were blunted increases with hypogonadism in phosphorylation of protein kinase B (AKTSer473) acutely after first RE (Z: 1.99 ± 0.5, P > 0.99 vs. P: 3.9 ± 0.8 fold change, P = 0.004) and after 6 weeks of RET (Z: 2.74 ± 0.6, P = 0.2 vs. P: 5.5 ± 1.1 fold change, P < 0.001, ES = 0.54, with significant differences between

Journal of Cachexia, Sarcopenia and Muscle 2021
DOI: 10.1002/jcsm.12843
Hypogonadism impairs exercise-induced muscle growth

Figure 3 Hypogonadism attenuates muscle protein turnover increases to RET. Values are means ± SEM. a = significantly different from baseline; b = significantly different between the two groups (Z: zoladex, P: placebo), P < 0.05. ABR, absolute breakdown rate; ASR, absolute synthetic rate; FGR, fractional growth rate; FSR, fractional synthesis rate; MPS, muscle protein synthesis; RET, resistance exercise training. See also Figure S3.

two groups (P = 0.01) and treatment-by-time interaction: P = 0.02, Figure 4B], and mammalian target of rapamycin (mTORSer2448) [Z: 1.9 ± 0.8, P > 0.99 vs. P: 3.6 ± 1 fold change, P = 0.002, ES = 0.53, with a trend in treatment-by-time interaction effect (P = 0.06), Figure 4C], and p70S6KThr389 (Z: 1.4 ± 0.2, P = 0.4 vs. P: 1.8 ± 0.2 fold change, P = 0.003,
Table 2: Mechano-signals cannot bypass blunted translational capacity in hypogonadism after resistance exercise training

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Week 1</th>
<th>Week 3</th>
<th>Week 6</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline</strong></td>
<td>528.1 (21.6)</td>
<td>522.6 (32.9)</td>
<td>564.6 (42)</td>
<td>595.8 (25.4)</td>
</tr>
<tr>
<td><strong>Week 1</strong></td>
<td>592.4 (25.4)</td>
<td>587.1 (23.7)</td>
<td>531.5 (31.2)</td>
<td>592.4 (24.3)</td>
</tr>
<tr>
<td><strong>Week 3</strong></td>
<td>592.4 (25.4)</td>
<td>587.1 (23.7)</td>
<td>531.5 (31.2)</td>
<td>592.4 (24.3)</td>
</tr>
<tr>
<td><strong>Week 6</strong></td>
<td>592.4 (25.4)</td>
<td>587.1 (23.7)</td>
<td>531.5 (31.2)</td>
<td>592.4 (24.3)</td>
</tr>
</tbody>
</table>

Values are means (SEM). Total RNA content (Z: 0.38 vs. P: P<0.0001, ES = Z:0.77, P<0.0001, treatment-by-time interaction: P = 0.02) was blunted after 6 weeks of RET with hypogonadism, with significant differences between two groups (P < 0.05). In addition, IGF-Iε (Z: P > 0.99 vs. P: P = 0.0005, ES = 0.72, treatment-by-time interaction: P = 0.04) and IGF-Iε (Z: P > 0.99 vs. P: P = 0.0005, ES = 0.68, treatment-by-time interaction: P = 0.08) expressions increased in P but were blunted with hypogonadism after 6 weeks of RET, with significant differences between two groups (P < 0.05). While mRNA expression of select myogenesis-related genes, that is, myogenin (Z: P > 0.99 vs. P: P = 0.002, ES = 0.72, treatment-by-time interaction: P = 0.05), Myf-5 (Z: P = 0.34 vs. P: P = 0.0001, ES = 0.81, treatment-by-time interaction: P = 0.07), and Myf-6 (Z: P = 0.11 vs. P: P = 0.01, ES = 0.79, treatment-by-time interaction: P = 0.01), were not changed with hypogonadism compared with P, C-met (Z: P = 0.03 vs. P: P < 0.0001, ES = 2.0.77, P=0.82) and C-Myc (Z: P = 0.007 vs. P: P = 0.01, ES = 2.0.74, P=0.74) increased in both groups, with no significant changes in MYOD and PAX-7 (P > 0.05). Nevertheless, a measure of myostatin (MSTN) displayed a trend to increase by 3 weeks in P (P = 0.01, ES = 0.55), with no significant changes at 6 weeks in either group (P > 0.05, Figure 5). Finally, there were no differences in the gene expression of mitochondrial transcription factor A (Tfam) or peroxisome proliferator-activated receptor γ co-activator-1α (PGC-1α) in either group (P > 0.05).

Hypogonadism impaired resistance exercise training-induced myogenic and androgenic, but not mitochondrial adaptations

Compared with P, AR (Z: P > 0.99 vs. P: P < 0.0001, ES = 0.85, treatment-by-time interaction: P = 0.006), HSD17β3 (Z: P > 0.99 vs. P: P = 0.007, ES = 1.04, treatment-by-time interaction: P = 0.02) was blunted after 6 weeks of RET with hypogonadism, with significant differences between two groups (P < 0.05). In addition, IGF-Iε (Z: P = 0.5 vs. P: P = 0.0005, ES = 0.72, treatment-by-time interaction: P = 0.04) and IGF-Iε (Z: P > 0.99 vs. P: P = 0.0005, ES = 0.68, treatment-by-time interaction: P = 0.08) expressions increased in P but were blunted with hypogonadism after 6 weeks of RET, with significant differences between two groups (P < 0.05). While mRNA expression of select myogenesis-related genes, that is, myogenin (Z: P > 0.99 vs. P: P = 0.002, ES = 0.72, treatment-by-time interaction: P = 0.05), Myf-5 (Z: P = 0.34 vs. P: P = 0.0001, ES = 0.81, treatment-by-time interaction: P = 0.07), and Myf-6 (Z: P = 0.11 vs. P: P = 0.01, ES = 0.79, treatment-by-time interaction: P = 0.01), were not changed with hypogonadism compared with P, C-met (Z: P = 0.03 vs. P: P < 0.0001, ES = 2.0.77, P=0.82) and C-Myc (Z: P = 0.007 vs. P: P = 0.01, ES = 2.0.74, P=0.74) increased in both groups, with no significant changes in MYOD and PAX-7 (P > 0.05). Nevertheless, a measure of myostatin (MSTN) displayed a trend to increase by 3 weeks in P (P = 0.01, ES = 0.55), with no significant changes at 6 weeks in either group (P > 0.05, Figure 5). Finally, there were no differences in the gene expression of mitochondrial transcription factor A (Tfam) or peroxisome proliferator-activated receptor γ co-activator-1α (PGC-1α) in either group (P > 0.05).
Figure 4  Mechano-signals cannot bypass blunted translational efficiency in hypogonadism after RET. Values are means ± SEM. a = significantly different from baseline; b = significantly different between the two groups (Z: zoladex, P: placebo), c = significantly different from Week 0, P < 0.05. RET, resistance exercise training.
Discussion

In the present study, chemically induced hypogonadism blunted augmentation in whole-body FFM gains after 6 weeks of RET, a well-established model of hypertrophy, with DXA data showing the impact of hypogonadism on different body composition components [i.e. FFM and total fat percentage (TFP)] (Figure 2II). The role of T in regulating FFM gains with RET has been contentious. For instance, West and Phillips reported that 12 weeks of RET increased FFM without altering endogenous T levels, concluding that changes in endogenous T levels did not impact RET-induced muscular adaptations. Conversely, 10 weeks of endogenous T suppression decreased FFM gains in young men, while in another study, T depletion to castration range for 12 weeks blunted muscle hypertrophy during 8 weeks of RET in young men. We conclude that induction of hypogonadism blunts whole-body muscle hypertrophy during RET. We also sought to determine changes in muscle architecture, focusing on the muscle undergoing sampling biopsies to seek molecular explanations for our findings. Reflecting whole-body data, RET-induced gains in MT, Lf and PA of the vastus lateralis (VL), and CSA of the quadriceps were blunted in the Z group. Increases in MT is an expected adaptive response to RET and it can be attributed to increases in both PA and Lf. However, the fact that no changes in PA or Lf after RET were reported in older men with lower T levels after 612, or 16 weeks of RET, and the association between low T levels and decline in MT, may underline T’s key role in RET-induced remodelling of thigh muscles. Indeed, our state of induced hypogonadism attenuated these aspects of muscle architectural adaptation and thigh muscle hypertrophic remodelling.

We also sought to investigate muscle fibre level remodelling and that noted hypertrophy (CSA) of type I fibres and a decrease in the relative ratio of type IIx fibres were blunted with hypogonadism. There was also a link between fibre type CSA, muscle hypertrophy, and T levels. Previous studies in young men have shown that fibre CSA (type I and II) increased after 12 weeks of RET and that this global hypertrophic response in both slow and fast muscle fibres has been attributed to T levels. Furthermore, injections of T (25–600 mg·week−1) for 20 weeks have been associated with increases in type I and II fibre CSA in young men. Type II fibres are more sensitive to physiological alteration; for example, loss of muscle mass with ageing is primarily due to the specific atrophy of muscle fibre type II, which is associated with lower satellite cell and myonuclei number. Indeed, satellite cell proliferation and the subsequent incorporation of their

Figure 5 Hypogonadism impaired RET-induced myogenic and androgenic, but not mitochondrial adaptations. (A) Heatmap of the changes in T metabolism, anabolism, myogenic, and myogenesis inhibitor gene expression from baseline to Week 6 of RET in Z and P. (B) Venn diagram of the overlap of differentially expressed genes briefly increased in Z, P, both, or neither. Values are means of fold changes normalized to a housekeeping gene (i.e. RPL13A), which exhibited high transcriptional stability over the study (between groups: \( P = 0.8 \); within both groups: \( P > 0.9 \)). a = significantly different from baseline; b = significantly different between the two groups (Z: zoladex, P: placebo), \( P < 0.05 \). RET, resistance exercise training.
differentiated progeny (i.e. newly formed myonuclei) are essential to allow muscle fibre type II hypertrophy.\textsuperscript{29} However, we did not observe any tendency towards changes in type IIa CSA with RET or hypogonadism, in line with lack of changes in satellite cell and myonuclei numbers. It seems, in our younger participants, the maximum amount of cytoplasm that can be controlled by one myonucleus, referred to as the ‘myonuclear domain’ ceiling,\textsuperscript{30} was already reached in type II fibres.\textsuperscript{28,29,31} In support of this proposition, fibre type CSA and proportion was unchanged after 30 and 90 days of RET in both young\textsuperscript{31} and older men.\textsuperscript{32} Conversely, fibre type II CSA increased while fibre type I CSA decreased after 12 weeks of RET,\textsuperscript{33} representing a significant discrepancy in the literature about the impacts of RET on myofibre adaptations.\textsuperscript{29,32} However, our data suggest that levels of endogenous T, in healthy young men, can be considered to be of paramount importance for the muscular adaptation (both global and local remodelling) to RET.

Muscular performance is the culmination of neural and muscle structural elements and is the most important attribute to physical function, which increased after 8 weeks of RET in young men.\textsuperscript{34} Herein, we established that hypogonadism attenuated gains in total dynamic (1-RM) strength, which were strongly correlated with endogenous T levels (Figure 2V.D), as was shown after 12 weeks of RET in middle-aged men.\textsuperscript{35} It had been reported that 12 weeks of chemical T castration coupled with 8 weeks of RET blunted strength gains in young men,\textsuperscript{14} through attenuating FFM gains rather than neural remodelling (Figure 2V.C). However, in contrast, other previous studies have shown that there may be a neural component to the effects of T, for example, increasing neurotransmitter synthesis, leading to increased strength and higher threshold motor unit discharge and less force fluctuation, which results in the recruitment of larger/faster motor units (fast twitch fibres).\textsuperscript{36} Our data illustrate that muscle mass gains were correlated with endogenous T levels; however, the lack of difference between the two experimental groups in specific strength per unit gains suggest blunted RET-induced FFM gains with hypogonadism were likely the major effector of performance deficits rather than other factors, for example, neural adaptations.

In comparison with the P group, hypogonadism attenuated MPS during RET while concomitantly blunting FBRs; crucially, net balance calculations illustrated that MPS > MPB in both groups (Figure 3). MPB is an important contributor to muscle remodelling and protein turnover, increasing after bouts of RE but to a lesser extent than MPS.\textsuperscript{5} The logical extrapolation of a sustained increase in net muscle protein deposition after RET is an increase in FFM and strength,\textsuperscript{12,13,37} in line with the gains in mass and strength in the P group in our study. Links between T and MPS have been long recognized. For instance, castration induced T withdrawal suppressed MPS components, decreasing muscle mass and strength in mice.\textsuperscript{38,39} Similarly, castration coupled to ‘rescue’ T replacement therapy for 2 weeks in mice indicated T as a key regulator of muscle protein turnover.\textsuperscript{38} However, in humans, it has previously been suggested that T supplementation may enhance net protein balance via an increase in MPS, with a trend towards an increase in MPB in young men.\textsuperscript{40} Conversely, 10 weeks of T suppression to within a hypogonadal range decreased whole-body protein synthesis and breakdown and IGF-1 expression, leading to decreased muscle strength and mass in young men\textsuperscript{52}; therefore, it may be expected that T removal may result in a decrease in MPB in humans. Herein, physiological endogenous T levels coupled to RET increased net protein accretion accompanied by increases in both MPS and MPB, with MPS > MPB indicating the central role of endogenous T in regulating RET-induced muscle protein turnover.\textsuperscript{17} These findings highlight that T play a permissive role for RET-induced increases in muscle protein turnover. To seek the underlying molecular transducers regulating this attenuated adaptive response, we investigated factors controlling intracellular protein turnover (i.e. protein translation, available mRNA, and transcriptional capacity), which reportedly have major effects on the rate of muscle hypertrophy.\textsuperscript{13}

Given that ribosomal RNA constitutes the major portion of total RNA (i.e. ~85%), an increase in total RNA content indicates reduced ribosomal (r) degradation (ribophagy)\textsuperscript{41} and/or enhanced r biogenesis and translational capacity through activation of rDNA transcription.\textsuperscript{42} rDNA transcription, which is the major rate limiting factor for ribosome production, is deemed essential for myofibre growth\textsuperscript{42} and also in hypertrophic responses to RE. In support of this is the observation of acute RE-induced increases in ribosomal RNA content increasing the ‘capacity’ for protein synthesis and promoting net protein balance, which are critical for anabolic potential and hypertrophy during RET.\textsuperscript{12,13} Indeed, ribosomal biogenesis is likely an important component of RET-induced muscle hypertrophy during longer-term RET in humans, that is, rRNA and ribosomal biogenesis increase after 8 weeks of RET in young men,\textsuperscript{43} while rRNA was claimed to be a key indicator of ribosomal biogenesis and a molecular transducer of muscle growth over 12 weeks of RET in young adults.\textsuperscript{44} Here, we demonstrate that increases in RNA content and RNA: DNA ratio, a reflection of ribosomal capacity (quantity of ribosome) for protein synthesis, were blunted in the Z group after RET. Similarly, the RNA:ASP (ASP: alkaline soluble protein) ratio, a measure of ribosomal efficiency,\textsuperscript{12} was attenuated with hypogonadism (Table 2). We previously showed that those who had lower normal T levels exhibited blunted ribosomal biogenesis and capacity as molecular transducers of 6 weeks of whole-body and unilateral RET\textsuperscript{12,13} and also, total muscle RNA was decreased in orchietomized rats.\textsuperscript{39} Thus, increases in total RNA content per ‘cellular unit’ (RNA: DNA ratio), an indicator of ribosomal abundance, and total RNA:ASP ratio, an index of synthetic capacity,\textsuperscript{1} require eugonadal levels of T, demonstrating the inability of RET to
augment translational activity in a hypogonadal milieu. To conclude, chemically induced hypogonadism blunted translational capacity, which may be partly responsible for the ‘anabolic resistance’ of muscle to RET with Z.

We next investigated aspects regulating the translational ‘efficiency’ of ribosomes corresponding to MPS, namely, the phosphorylation of key (e.g. mTOR) adaptive signalling networks at ‘snap-shot’ periods during the study (i.e. first and last RE bouts) in both placebo and Zoladex groups. In doing so, we are quantifying the effects of acute RE on the background of chronic eugonadal and hypogonadal states. As such, a notable interpretative limitation is that we are unable to determine if measured effects are due to acute effects of RE, and/or the chronic background of our interventions. Nonetheless, in making these measures, we noted ‘RE-induced’ activation of numerous molecular transducers of muscle growth were blunted in hypogonadism, and in a similar fashion to individuals who have lower endogenous levels (i.e. older vs. young men, although this is speculative) as well as in castrated mice. The anabolic effects of androgens on skeletal and cardiac muscle are reported to be mediated via mTORC1 pathways, and it is speculated that the generalized impaired activation of, for example, mTORC1, ERK1/2, and MAPK growth pathways could have resulted in blunted muscle fibre hypertrophy and RE-induced increases in total RNA content (Table 2) observed. Finally, some studies report that castration is associated with an increase in MPB pathways in mice (e.g. AMPKε). However, we show that RET activates both anabolic and catabolic pathways with MPS > MPB and with hypogonadism blunting both MPS (e.g. mTOR pathway) and MPB, which lead to reduce the absolute positive shift in protein balance after RE bouts and attenuating increases in muscle mass over RET.

We show steroidogenesis enzyme expression to be blunted after 6 weeks of RET in a hypogonadal environment. Single bout (i.e. acute) of RE did not change muscle steroidogenic enzyme expression in young men. Although 12 weeks of RET increased intramuscular steroidogenic enzyme levels in young men and also restored age-associated reductions in muscle sex steroid hormone levels and muscle steroidogenic enzyme expression in older men, which correlated with increases in muscle strength and CSA, we have already shown that 6 weeks of RET was not a potent enough stimulus to overcome age-associated andropause in older men. Herein, hypogonadism attenuated the RET induction of AR mRNA and protein levels possibly resulting in lower muscle T processing capacity due to lower T in the circulation. Because androgen-bound AR alters mRNA expression of many molecular exercise transducers, for example, myogenesis, and is associated with triggering anabolic kinase signalling, that is, Akt, the fact that its expression is blunted at both the gene and protein levels with hypogonadism would suggest translational and transcriptional links between endogenous T and changes in MPS, FFM, and strength in this present study and others. We also demonstrate that anabolic and myogenic-related gene expression are blunted during chemically induced hypogonadism even during RET, that is, represented by blunted IGFR-1E and IGFR-1Ec expression, because IGFR-1Ec is purported to correlate with increased translation and promote myogenesis differentiation, while IGFR-1Ec expression is associated with transcriptional activity and also initiation of satellite cell proliferation. T suppression for 10 weeks decreased IGFR-1 mRNA concentration in young men, indicating a possible link between the IGFR-1 axis and T levels, and other anabolic genes. In the present study, in line with past work in older adults, we also show that hypogonadism is associated with the attenuation of the expression of myogenic regulatory factors (MRFs) after 6 weeks of RET, in line with blunting of both MPS and whole-body hypertrophy. This supports previous work demonstrating a pro-myogenic role for T; for example, T increased the transformation of pluripotent precursor cells towards a myogenic lineage. We report an augmentation in C-Myc expression in both experimental groups. It is reported C-Myc expression is highly sensitive to RET and ablation of T decreased C-Myc mRNA in orchietomized rats; however, hypogonadal T levels in our study do not blunt its increased expression during RET. This seems an unlikely feature of blunted muscle hypertrophy in our study, while we showed chemically induced hypogonadism blunted transcriptional capacity components during 6 weeks of RET. However, it is reported that muscle growth is characterized more by translational, than transcriptional regulation. Finally, because T up-regulates cellular bioenergetics via increases in ATP synthesis and mitochondrial content that are associated with increases in mitochondrial biogenesis and androgen deficiency contributes to the pathophysiology of ‘mitochondrial dysfunction’, we investigated any potential impacts of hypogonadism during RET upon mitochondrial adaptations (i.e. mitochondrial biogenesis and function). It has been reported that RET stimulates mitochondrial biogenesis; that is, 10 weeks of RET augmented mitochondrial biogenesis, albeit to a lesser extent than endurance training. In our study, neither RET nor hypogonadism were associated with alteration in cellular bioenergetics, as determined by mitochondrial oxidative phosphorylation (OXPhos) blots. In line with this, we observed no differences in the gene expression of mitochondrial transcription factor A (Tfam) or peroxisome proliferator-activated receptor γ co-activator-1α (PGC-1α). Thus, while castration-induced AR changes were associated with decreases in Tfam and PGC-1α at the level of both protein and gene expression in animal models, we observed no association between hypogonadism and cellular bioenergetics during RET at either the transcriptional (Figure 5) or translational levels (Figure S4). As such, impaired cellular bioenergetics and mito-
chondrial biogenesis induction by hypogonadism would both seem unlikely causes of the blunted muscle hypertrophic response we observe in this study.

We acknowledge limitations to our study. Firstly, not measuring corresponding total protein pools alongside phosphorylated signalling proteins is considered as limitation of our study though does not detract from our data showing the importance of T in bolstering MPS-related signalling activity and by extension, exercise-induced muscle growth during RET. Also, biopsy timings within this study reflect acute responses to RE and how these adapt over time and do not demonstrate how resting levels of gene and signalling protein activation may change with RET. Thus, further time-course biopsies (e.g. at resting stage over RET) would lead to a more complete understanding of the molecular responses to RET adjuvant to hypogonadism.

Conclusions

T suppression via a single GnRh analogue injection was well tolerated by the volunteers and demonstrated the negative impact of hypogonadism on muscle hypertrophic programming via blunting the normal responses of muscle molecular transducers, that is, anabolic signalling proteins (mTOR pathway), T processing enzymes (HSDs), pro-myogenic gene expression, which result in an increase in the capacity for protein synthesis (e.g. RNA biogenesis), and consequently MPS. Thereby, we demonstrate the importance of endogenous T in adopting a permissive role in regulating both muscle protein turnover and hypertrophy, which is not resuable by mechano-transduction alone. From a gender perspective, T is also important in regulating muscle mass and strength in women, with acute increases in T levels in women being reported in some studies in response to RE but not all.54 However, further studies are needed to investigate the effects of endogenous T upon muscle quality/programming in premenopausal women.

Funding

This work was supported by the Medical Research Council (grant numbers MR/R502364/1 and MR/P021220/1) as part of the MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research awarded to the Universities of Nottingham and Birmingham, and the National Institute for Health Research, Nottingham Biomedical Research Centre.

Acknowledgements

The authors are grateful for the clinical and technical support of Amanda Gates, Ciaran Padhiar, and Dr Martino Franchi. The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.55

Online supplementary material

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Figure S1 (related to Figure 2).** Induced hypogonadism attenuates muscle growth and functional adaptations to RET. Values are means ± SEM. a = significantly different from baseline; b = significantly different between the two groups (Z: zoladex, P: placebo), P < 0.05. FFM: fat free mass, TFM: total fat mass, CSA: cross sectional area, MVC: maximal voluntary contraction, RET: resistance exercise training.

**Figure S2 (related to Figure 2).** Muscle cross-section stained for fibre type-specific identification of satellite cells. Satellite cells are stained brown with Pax7 antibody, whereas laminin and type I fibres are stained with fluorescent green and type IIA fibres with fluorescent red. Myonuclei are stained blue (DAPI).

**Figure S3 (related to Figure 3).** Hypogonadism attenuates muscle protein turnover increases in response to RET. Values are means ± SEM. b = significantly different between two groups (Z: zoladex, P: placebo), P < 0.05. FBR: fractional breakdown rate, RET: resistance exercise training.

**Figure S4 (related to Figure 4).** Mechano-signals cannot bypass blunted translational efficiency in hypogonadism after RET. Values are means ± SEM. a = significantly different from baseline; b = significantly different between the two groups (Z: zoladex, P: placebo), P < 0.05. NDUFB8: NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, SDHB: Succinate dehydrogenase [ubiquinone] iron–sulfur subunit, UQCR2: Cytochrome b-c1 complex subunit 2, MTCO1: Mitochondrially encoded cytochrome c oxidase I, ATP5A: ATP synthase F1 subunit alpha, RET: resistance exercise training.

**Table S1.** Primer sequences for each of the probed genes used in PCR.

**Table S2.** Key resources.

Conflict of interest

The authors have declared that no conflict of interest exists.
References


